Helping Artificial Valves Keep Pace with Growing Children: FDA Approves Expandable Pulmonary Valve

For children who need pulmonary valve replacement, growth can sometimes mean that the next surgery is drawing closer: as their bodies grow, an artificial valve that once fit may become too small. On October 1, the U.S. Food and Drug Administration (FDA) approved Edwards Lifesciences’ AUTUS size-adjustable valve for children with congenital pulmonary valve disease, adding a treatment option that can be resized after implantation.

The valve still requires surgery for its initial implantation, but it can subsequently be expanded through a less invasive balloon catheter procedure. According to the FDA, its diameter at implantation can be as small as approximately 13 millimeters and later expanded to 22 millimeters, approaching the size of an adult pulmonary valve. It does not grow on its own; instead, it allows the medical team to adjust the diameter of the existing valve as a child grows.

Another change lies inside the valve. The leaflets that open and close to control blood flow are made of a synthetic polymer, replacing the animal tissue commonly used in traditional valves. The FDA said this is the first heart valve with polymer leaflets approved in the United States. Animal tissue is more prone to hardening and degeneration in children, so the new material offers another design approach. However, short-term results cannot establish whether it is more durable than existing materials.

The study supporting the approval enrolled 62 children at 12 centers in the United States. The FDA noted that implantation was successful in all patients. At six-month follow-up, the first 60 patients enrolled had hemodynamic performance within an acceptable range and no more than mild valve regurgitation. These results support early functional performance but are not yet sufficient to answer whether the valve can serve patients through many years of growth.

Edwards also announced that the study met its primary safety and effectiveness endpoints, with no patients experiencing device-related complications within 30 days and no reinterventions on the AUTUS valve within six months. Among those who completed one-year follow-up, all had a mean right ventricular outflow tract pressure gradient of no more than 40 millimeters of mercury, less than moderate pulmonary valve regurgitation, and no valve reintervention. However, the announcement did not specify how many patients had completed one-year follow-up, so incomplete follow-up remains a limitation when interpreting these results.

The safety data also contain signals that require further investigation. The FDA and MedTech Dive reported that three patients in the study experienced valve frame fractures, while two other patients had reduced movement of one leaflet; none caused symptoms at the time. In addition, two children developed worsening valve function as they grew and subsequently underwent successful expansion without another open-heart surgery. These two cases demonstrate the design’s clinical feasibility, but experience with expansion remains very limited.

For families, one fewer open-heart surgery could mean one fewer hospital stay and recovery period. For this new valve, the real test is whether it can continue to maintain blood flow and closure function after expansion. Edwards said the study will follow patients for ten years. This approval brings a size-adjustable valve into clinical use, while long-term durability, the subsequent effects of frame problems, and how many surgeries it can actually prevent remain questions requiring longer follow-up and data from more patients.